A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Universe Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
UPC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.17 Med: -0.18 Max: 0.31
Current: -3.17
During the past 8 years, the highest Debt-to-EBITDA Ratio of Universe Pharmaceuticals was 0.31. The lowest was -3.17. And the median was -0.18.
UPC's Debt-to-EBITDA is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs UPC: -3.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Universe Pharmaceuticals Debt-to-EBITDA Related Terms
Universe Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CPMD, SHPH, NPHC: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2025) EBITDA data.
Universe Pharmaceuticals (UPC) has a Debt-to-EBITDA of -128.57 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Universe Pharmaceuticals. According to the industry distribution chart, Universe Pharmaceuticals ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Universe Pharmaceuticals' Debt-to-EBITDA too high?
Universe Pharmaceuticals' current Debt-to-EBITDA is -128.57. Based on the distribution chart, Universe Pharmaceuticals ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Debt-to-EBITDA compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Universe Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Universe Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Debt-to-EBITDA is -128.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Fairly Valued. The stock's GF Value™ is $5.17, compared to a current price of $5.19 — trading 0.4% above its estimated fair value. The current Debt-to-EBITDA is -128.57. Universe Pharmaceuticals' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Debt-to-EBITDA is -128.57 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.19 is trading 0.4% above its estimated GF Value™ of $5.17.
GuruFocus considers Universe Pharmaceuticals to be Fairly Valued.
Key valuation signals for UPC:
Debt-to-EBITDA: -128.57
GF Value™: $5.17 vs. price of $5.19 (0.4% above fair value)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
64GF Score
Get the complete analysis for UPC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
